Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Environmental Science
Link
http://link.springer.com/content/pdf/10.1007/s13691-019-00389-z.pdf
Reference17 articles.
1. Srigley JR, Eble JN (1998) Collecting duct carcinoma of kidney. Semin Diagn Pathol 15:54–67
2. Sui W, Matulay JT, Robins DJ et al (2017) Collecting duct carcinoma of the kidney: disease characteristics and treatment outcomes from the National Cancer Database. Urol Oncol 35:540.e13–540.e18
3. Atkins MB, Clark JI, Quinn DI (2017) Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann Oncol 28:1484–1494
4. Escudier B (2019) Combination therapy as first-line treatment in metastatic renal-cell carcinoma. N Engl J Med 380:1176–1178
5. Motzer RJ, Tannir NM, McDermott DF (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney;Clinical Genitourinary Cancer;2024-08
2. Establishment of a nomogram to predict the overall survival of patients with collecting duct renal cell carcinoma;Discover Oncology;2024-07-04
3. Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report;Journal of Pharmaceutical Health Care and Sciences;2024-05-31
4. Surgery lengthens survival for collecting duct carcinoma: Analysis of Hospital-Based Cancer Registry data in Japan;2024-04-12
5. Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma;Canadian Urological Association Journal;2024-01-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3